BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 29448044)

  • 21. Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.
    Hashimoto Y; Yagi K; Kondoh M
    Pflugers Arch; 2017 Jan; 469(1):45-53. PubMed ID: 27629072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.
    Brodzik R; Glogowska M; Bandurska K; Okulicz M; Deka D; Ko K; van der Linden J; Leusen JH; Pogrebnyak N; Golovkin M; Steplewski Z; Koprowski H
    Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8804-9. PubMed ID: 16720700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGF regulates claudin-2 and -4 expression through Src and STAT3 in MDCK cells.
    García-Hernández V; Flores-Maldonado C; Rincon-Heredia R; Verdejo-Torres O; Bonilla-Delgado J; Meneses-Morales I; Gariglio P; Contreras RG
    J Cell Physiol; 2015 Jan; 230(1):105-15. PubMed ID: 24909426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding and functional properties of a mouse-human chimeric monoclonal antibody of the human IgG1 subclass with specificity for human carcinomas.
    Liao SK; Horton L; Flahart RE; O'Rear L; Crumpacker D; Imbaratto JW; Yannelli JR; Robinson RR; Oldham RK
    Hum Antibodies Hybridomas; 1990; 1(2):66-76. PubMed ID: 2103354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy.
    Ochi F; Fujiwara H; Tanimoto K; Asai H; Miyazaki Y; Okamoto S; Mineno J; Kuzushima K; Shiku H; Barrett J; Ishii E; Yasukawa M
    Cancer Immunol Res; 2014 Mar; 2(3):249-62. PubMed ID: 24778321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue distribution and safety evaluation of a claudin-targeting molecule, the C-terminal fragment of Clostridium perfringens enterotoxin.
    Li X; Saeki R; Watari A; Yagi K; Kondoh M
    Eur J Pharm Sci; 2014 Feb; 52():132-7. PubMed ID: 24231339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
    Preithner S; Elm S; Lippold S; Locher M; Wolf A; da Silva AJ; Baeuerle PA; Prang NS
    Mol Immunol; 2006 Mar; 43(8):1183-93. PubMed ID: 16102830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.
    Van den Hoecke S; Ehrhardt K; Kolpe A; El Bakkouri K; Deng L; Grootaert H; Schoonooghe S; Smet A; Bentahir M; Roose K; Schotsaert M; Schepens B; Callewaert N; Nimmerjahn F; Staeheli P; Hengel H; Saelens X
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
    Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
    MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
    Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
    Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Claudin Antibodies as a Concept for Development of Claudin-Directed Drugs.
    Hashimoto Y; Okada Y; Shirakura K; Tachibana K; Sawada M; Yagi K; Doi T; Kondoh M
    J Pharmacol Exp Ther; 2019 Feb; 368(2):179-186. PubMed ID: 30530622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen.
    Huang X; Bennett M; Thorpe PE
    Prostate; 2004 Sep; 61(1):1-11. PubMed ID: 15287089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth.
    Qiu Y; Zhang Z; Shi J; Liu S; Liu Y; Zheng D
    IUBMB Life; 2012 Sep; 64(9):757-65. PubMed ID: 22815059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.
    Braster R; Grewal S; Visser R; Einarsdottir HK; van Egmond M; Vidarsson G; Bögels M
    PLoS One; 2017; 12(5):e0177736. PubMed ID: 28542406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection.
    Ramadhany R; Hirai I; Sasaki T; Ono K; Ramasoota P; Ikuta K; Kurosu T
    Antiviral Res; 2015 Dec; 124():61-8. PubMed ID: 26522769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
    Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
    Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
    Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current progress in a second-generation claudin binder, anti-claudin antibody, for clinical applications.
    Hashimoto Y; Yagi K; Kondoh M
    Drug Discov Today; 2016 Oct; 21(10):1711-1718. PubMed ID: 27422269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.